Adderall (mixed salts of a single-entity amphetamine)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Supplemental NDA Approved February 1996
Attention Deficit/Hyperactivity Disorder (ADHD)
Adderall has been indicated for use in children three years of
age and older with ADHD as an integral part of a total treatment
program which typically includes psychological, educational, and
Adderall may improve attention span, decrease distractibility,
and increase the ability to follow directions and finish tasks. The
therapy may also improve the subject's ability to think before
acting (decrease impulsivity), decrease hyperactivity and improve
legibility of handwriting. In addition, aggression may decrease in
youngsters with ADHD.
Adderall is available in 10 mg and 20 mg double-scored
Adderall is generally well tolerated with few adverse reactions
reported. The most frequently reported adverse reactions include
anorexia, insomnia, stomach pain, headache, irritability, and
weight loss. As with most psychostimulants indicated for ADHD, the
possibility of growth suppression and the potential for
precipitating motor tics and Tourette Syndrome exists with Adderall
treatment, and in rare cases exacerbations of psychosis have been
reported. Since psychostimulants have a high potential for abuse,
Adderall should only be prescribed as part of an overall treatment
program for ADHD with close physician supervision.
Adderall had previously been approved and marketed by another
company under the name of Obetrol, indicated for exogenous obesity
and ADHD. Richwood acquired the company, including the formulation
and manufacturing rights to Obetrol, and renamed the product
Adderall in 1994.